AzTrials
AzTrials

ChildNCT02616419

External Cold and Vibration Stimulation (Buzzy®) for Procedural Pain Management in Children Undergoing Needle-Related Procedures

A study testing Buzzy® device and Maxilene® (Lidocaine liposomal 4%) in people with Child and Pain Due to Certain Specified Procedures, run by St. Justine's Hospital at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Since the late 1980s, several studies focused on pediatric procedural pain and show that it still underevaluated and undertreated, especially in the Emergency Department (ED). Needle-related procedures are the most important source of pain and anxiety and children. Read more about this study

Who is it for?
Ages 4 to 17 years
What is being tested?
Buzzy® device and Maxilene® (Lidocaine liposomal 4%)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
354 participants
Where
1 siteCanada
Study dates
15 May 2017to 30 Sep 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Between the ages of 4 and 17 years old
  • Visiting the Emergency Department
  • Requiring a venipuncture or IV catheter insertion
  • Able to understand and speak French or English
  • Having at least one parent who can understand, read and talk in French or English

Who cannot join

  • Neuro-cognitive disability that precludes patients from assenting and participating to the study
  • Inability to self-report pain
  • Critical or unstable health status

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • CHU Ste-Justine

    Montreal, Quebec

Other trials in Canada

About this study

Official title: External Cold and Vibration Stimulation (Buzzy® Device) VS Topical Anesthetic Cream for Procedural Pain Management in Children Undergoing Needle-Related Procedures in the Emergency Department : A Randomized Controlled Non-Inferiority Trial

Since the late 1980s, several studies focused on pediatric procedural pain and show that it still underevaluated and undertreated, especially in the Emergency Department (ED). Needle-related procedures are the most important source of pain and anxiety and children. Since it is impossible to completely eliminate the pain and anxiety experienced by children during painful procedures, use of non-pharmacological and/or pharmacological interventions might be beneficial. Most methods used for relief of procedural pain and anxiety for children require time or extra staff, which represent barriers to their implantation in the ED. An easy-to-use and rapid non-pharmacological intervention could overcome these constraints and optimize procedural pain and anxiety relief in children undergoing a needle-related procedure.

The primary objective of this study is to determine if a device combining cold and vibration (Buzzy®) is non-inferior (no worse) than a topical anesthetic cream (lidocaine liposomal 4%) for procedural pain management in children undergoing needle-related procedures in the ED.

Investigators strongly believe that the use of the Buzzy® device in the ED will improve significantly the pain and anxiety felt by children undergoing needle-related procedures. Since EDs are usually chaotic and very busy, an easy-to-use and rapid non-pharmacological intervention like the Buzzy®, will surely be adopted by the nursing personnel as a useful tool for procedural pain. Given this knowledge, the investigators feel that this randomized controlled trial will have the potential to improve nursing practice and optimize painful experiences of children undergoing needle-related procedures.

Read the detailed description

Since the 1980s, several researches focused on paediatric procedural pain to learn more about its nature, its causes, its consequences, its assessment and treatment. However, decades later, it is still undervalued and undertreated, especially in the Emergency Department (ED). Thus, children experience a high level of pain and anxiety in the ED during painful procedures, which could be due to multiple factors: lack of knowledge regarding pain management interventions, lack of time, work overload, limited space and interruption in the continuity of care.

Needle-related procedures (venipuncture, IV access, s/c, IM) are the most important sources of pain and distress in children. A study shows that only 31% of children benefit from procedural pain management during the insertion of an IV access and less than 1% during a venipuncture. Inadequate procedural pain and anxiety relief in children is not without consequences. These effects may be physiological, psychological and emotional and can have long-term impact. Since it is impossible to completely eliminate the pain and anxiety experienced by children during needle-related procedures, relief through non-pharmacological and/or pharmacological interventions is essential.

Most relief methods of procedural pain and anxiety available for children require much time or staff, which represent barriers regarding their implantation in the ED. The use of a rapid and easy-to-use non-pharmacological intervention could overcome these constraints and optimize procedural pain and anxiety relief in children. In 2009, a new device (Buzzy®), combining cold (ice wings) and vibration (bee's body), was developed in the USA for the relief of pediatric procedural pain. This device relies on the Gate Control Theory as well as diffuse noxious inhibitory control for the modulation of pain response (Baxter et al., 2009). Efficacy of the Buzzy® device in pediatric patients in the ED has only been evaluated in two studies up to this date. Both studies showed significant results regarding control of post-procedural pain and post-procedural anxiety. So far, no study has been conducted in Canada and none has compared the effects of Buzzy. Since the 1980s, several researches focused on pediatric procedural pain to learn more about its nature, its causes, its consequences, its assessment and treatment. However, decades later, it is still undervalued and undertreated, especially in the Emergency Department (ED). Thus, children experience a high level of pain and anxiety in the ED during painful procedures, which could be due to multiple factors: lack of knowledge regarding pain management interventions, lack of time, work overload, limited space and interruption in the continuity of care.

Needle-related procedures (venipuncture, IV access, s/c, IM) are the most important sources of pain and distress in children. A study shows that only 31% of children benefit from procedural pain management during the insertion of an IV access and less than 1% during a venipuncture. Inadequate procedural pain and anxiety relief in children is not without consequences. These effects may be physiological, psychological and emotional and can have long-term impact. Since it is impossible to completely eliminate the pain and anxiety experienced by children during needle-related procedures, relief through non-pharmacological and/or pharmacological interventions is essential.

Most relief methods of procedural pain and anxiety available for children require much time or staff, which represent barriers regarding their implantation in the ED. The use of a rapid and easy-to-use non-pharmacological intervention could overcome these constraints and optimize procedural pain and anxiety relief in children. In 2009, a device (Buzzy®), combining cold (ice wings) and vibration (bee's body), was developed in the USA for the relief of pediatric procedural pain. This device relies on the Gate Control Theory as well as diffuse noxious inhibitory control for the modulation of pain response (Baxter et al., 2009). The few study that have evaluated its efficacy presents several limitations, such as small sample size and absence of intervention in control group. To date, no study has been conducted in Canada and none has compared its effects with the gold standard intervention for needle-related procedures, the topical anesthetic cream.

Objective:

The primary aim of this study is to determine if a device combining cold and vibration (Buzzy®) is non-inferior (no worse) than lidocaine liposomal 4% for procedural pain management in children undergoing needle-related procedures in the ED.

Methods:

Design: This study is a two-arm, randomized, controlled, non-inferiority trial. Setting: Pediatric ED in a university health center in Montreal. Inclusion criteria: Investigators will include children: 1) Ages from 4-17 years old; 2) Visiting the ED; 3) Requiring a needle-related procedure (venipuncture or IV catheter insertion); 4) Understanding and speaking either French or English; 5) Having at least one parent (or legal guardian) who understands, read and talks in French or English. Exclusion criteria: Investigators will exclude children with: 1) A neuro-cognitive impairment that precludes informed consent and/or assent, 2) An inability to self-report pain, 3) A critical or unstable health. Interventions: Arm 1 (Buzzy® device): Just before the needle-related procedure, the Buzzy® device (combining an ice pack and vibration integrated to a plastic bee) will be applied 5 cm above needle insertion site and will be maintained in place throughout the painful procedure. Arm 2 (lidocaine liposomal 4%): The topical anesthetic cream will be applied 30 minutes before the needle-related procedure on the insertion site. Randomization and Allocation: A independent biostatistician will generate the sequence of randomization stratified by age (4-7; 8-12; 13-17) and using permuted block sizes for each stratum. Enrolled participants will be randomly assigned to one of the two arms with a 1:1 allocation ratio. Sample size: Using a non-inferiority margin of 0.7 on a scale 0 to 10 for mean per-procedural pain, a total of 380 participants (190/group) will be necessary to achieve a power of 90% at the one-sided 5% significance. Primary outcome: The primary outcome will be the mean per-procedural pain scores on the Color Analogue Scale (CAS). Secondary outcomes: a) Mean per-procedural pain scores on Faces-Pain Scale Revised (FPS-R), b) Mean level of per-procedural distress using the Procedure Behavior Check List (PBCL) and the Children's Fear Scale (CFS), c) Memory of pain 24 hours after the needle-related procedure on the FPS-R. d_ Proportion of children with success of the needle-related procedure at first attempt, e) Self-reported levels of satisfaction of children, parents and nurses with questionnaires previously developped by our team. Analyses: All analyses will be performed under both intention-to-treat and per-protocol principles. Regarding the primary outcome, the mean difference in pain scores between the experimental group ( Buzzy® device) and the control group (lidocaine liposomal 4%) along with its lower confidence limit will be calculated. If this limit lies within (-∞,0.7), then the null hypothesis of inferiority will be rejected in favor of the alternative hypothesis at the 5% significance level. A similar approach will be used for the secondary outcomes (a, b, c). Proportion of children with success of the procedure at first attempt will be compared using a chi-square test. Descriptive statistics will be used to report data on satisfaction. ANCOVA will be performed on covariate to increase statistical power. Subgroups analyses will be performed according to age groups (4-7; 8-12; 13-17).

Relevance :

This proposed work will be the first RCT in Canada to assess the efficacy of the Buzzy® device for procedural pain and anxiety relief in children undergoing needle-related procedure. Very few studies of pharmacological and non-pharmacological interventions exist, but no intervention have been identified to be optimal for pain and anxiety management in the context of an ED. Investigators strongly believe that the use of the Buzzy® device in children undergoing needle-related procedures would optimize nursing practice and improve pain and anxiety experienced by children during their visit to the ED.

Being tested
Buzzy® device, Maxilene® (Lidocaine liposomal 4%)
Keywords
Emergency Department, Procedural pain, Procedural anxiety, Needle-related procedures, Clinical Nursing Research, Nursing practice, Non-pharmacological method
Medical subject headings
Emergencies, Pain, Procedural

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Buzzy® deviceDevice

    Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.

  • Maxilene® (Lidocaine liposomal 4%)Drug

    Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.

Study groups in NCT02616419
Study groupRoleWhat they receive
Buzzy® deviceExperimentalJust before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
Receives: Device: Buzzy® device
Maxilene® (Lidocaine liposomal 4%)Active comparatorMaxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
Receives: Drug: Maxilene® (Lidocaine liposomal 4%)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean per-procedural pain scores

    The per-procedural pain intensity will be assess immediately after the needle-related procedure using the Color Analogue Scale (CAS) (self-report scale).

    Measured: T-3: Immediately after the-needle-related procedure

Secondary outcomes (6)
  1. Mean per-procedural pain scores

    The per-procedural pain intensity will be assess immediately after the needle-related procedure using the Faces Pain Scale-Revised (FPS-R) (self-report scale).

    Measured: T-3: Immediately after the needle-related procedure

  2. Mean level of per-procedural distress

    The level of per-procedural distress will be assess during the needle-related procedure using the Procedure Behavior Check List (PBCL) (observational scale).

    Measured: T-2: During the needle-related procedure

  3. Mean level of per-procedural distress

    The level of per-procedural distress will be assess immediately after the needle-related procedure using the Children's Fear Scale (CFS) (self-report scale).

    Measured: T-3: Immediately after the needle-related procedure

  4. Satisfaction regarding the use of the Buzzy® device

    The satisfaction of the nurses, children and parents regarding the use of the Buzzy® device will be assess after the needle-related procedure with questionnaires previously developped by the investigators.

    Measured: T-4: 15 minutes after the needle-related procedure

  5. Memory of pain (mean post-procedural pain scores 24 hours after the procedure)

    The memory of pain will be assess 24 hours after the needle-related procedure using the Faces-Pain Scale-Revised (FPS-R) (self-report scale).

    Measured: T-5: 24 hours after the needle-related procedure

  6. Proportion of participants with success of the needle-related procedure at the first attempt

    The success of the needle-related procedure at first attempt will be assess using dichotomized (yes/no) clinical data immediately after the needle-related procedure.

    Measured: T-3: Immediately after the needle-related procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2015 (estimated)
  2. Study start15 May 2017
  3. Primary completion30 Sep 2018
  4. Study completion30 Sep 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
354 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02616419
Sponsor's protocol ID
2017-1405
Status last verified
Aug 2019
First submitted
23 Nov 2015
Last updated
6 Aug 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes

Publications

  • Ballard A, Khadra C, Adler S, D Trottier E, Bailey B, Poonai N, Theroux J, Le May S. External cold and vibration for pain management of children undergoing needle-related procedures in the emergency department: a randomised controlled non-inferiority trial protocol. BMJ Open. 2019 Jan 15;9(1):e023214. doi: 10.1136/bmjopen-2018-023214.

    PubMed 30782698

Questions about this trial

What is this clinical trial studying?

A study testing Buzzy® device and Maxilene® (Lidocaine liposomal 4%) in people with Child and Pain Due to Certain Specified Procedures, run by St. Justine's Hospital at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean per-procedural pain scores (time frame: T-3: Immediately after the-needle-related procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02616419, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in